340B Drug Pricing Program
AHA President and CEO Rick Pollack joined AHA’s Chad Golder, senior vice president and general counsel, Travis Robey, vice president of political affairs, and Shannon Wu, director of payment policy, for a discussion on the ever-shifting landscape of health care affairs on Capitol Hill.
Please ask your senators and representatives to prevent Medicaid disproportionate share hospital payment cuts from taking effect; extend enhanced low-volume adjustment and Medicare-dependent hospital programs that expand access to care in rural areas; and extend telehealth and hospital-at-home…
Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for patients in vulnerable communities.
AHA 340B Advocacy Alliance for January 7, 2025
AHA 340B Advocacy Alliance Bulletin for January 6, 2025.
AHA shares feedback in response to the Centers for Medicare & Medicaid Services’ information collection request (ICR) regarding the Medicare Transaction Facilitator (MTF) and the Medicare drug negotiation program.
Our Lady of the Lake Health, a part of the Franciscan Missionaries of Our Lady Health System, has been a leading provider of high-quality care in the Baton Rouge community for more than 100 years.
The Health Resources and Services Administration last week directed Sanofi to cease implementation of its 340B rebate proposal immediately and to inform HRSA of its plans no later than Dec. 20 in order to provide adequate notice to covered entities.
AHA 340B Advocacy Alliance Bulletin for December 16, 2024.
The net prices of five drugs included in a new study from the Institute for Clinical and Economic Review increased without clinical justification in 2023. These increases led to $815 million incremental added costs for U.S. payers.